Correlation of Plasma EGF with Striatal Dopamine Transporter Availability in Healthy Subjects

[1]  P. Wee,et al.  Epidermal Growth Factor Receptor Cell Proliferation Signaling Pathways , 2017, Cancers.

[2]  D. Krainc,et al.  α-synuclein toxicity in neurodegeneration: mechanism and therapeutic strategies , 2017, Nature Medicine.

[3]  Alan J. Thomas,et al.  Autopsy validation of 123I-FP-CIT dopaminergic neuroimaging for the diagnosis of DLB , 2017, Neurology.

[4]  G. Bråthen,et al.  Alpha-synuclein measured in cerebrospinal fluid from patients with Alzheimer’s disease, mild cognitive impairment, or healthy controls: a two year follow-up study , 2016, BMC Neurology.

[5]  F. N. Emamzadeh.  Alpha-synuclein structure, functions, and interactions , 2016, Journal of research in medical sciences : the official journal of Isfahan University of Medical Sciences.

[6]  J. Trojanowski,et al.  Plasma EGF and cognitive decline in Parkinson's disease and Alzheimer's disease , 2016, Annals of clinical and translational neurology.

[7]  P. Zipfel,et al.  Apolipoprotein e affects neuronal alpha-synuclein uptake in an isoform-dependent manner , 2015, Alzheimer's & Dementia.

[8]  Huidong Tang,et al.  Plasma epidermal growth factor decreased in the early stage of Parkinson's disease. , 2015, Aging and disease.

[9]  F. Carrillo,et al.  Elaboración de una plantilla de SPM para la normalización de imágenes de SPECT con 123I-Ioflupano , 2013 .

[10]  Huaxi Xu,et al.  Apolipoprotein E and Alzheimer disease: risk, mechanisms and therapy , 2013, Nature Reviews Neurology.

[11]  E. Park.  A New Era of Clinical Dopamine Transporter Imaging Using 123I-FP-CIT* , 2012, The Journal of Nuclear Medicine Technology.

[12]  D. Dickson.  Parkinson's disease and parkinsonism: neuropathology. , 2012, Cold Spring Harbor perspectives in medicine.

[13]  P. Spano,et al.  Redistribution of DAT/α-Synuclein Complexes Visualized by “In Situ” Proximity Ligation Assay in Transgenic Mice Modelling Early Parkinson's Disease , 2011, PLoS ONE.

[14]  A. Singleton,et al.  The Parkinson Progression Marker Initiative (PPMI) , 2011, Progress in Neurobiology.

[15]  H. Nawa,et al.  Qualitative and quantitative re‐evaluation of epidermal growth factor‐ErbB1 action on developing midbrain dopaminergic neurons in vivo and in vitro: target‐derived neurotrophic signaling (Part 1) , 2011, Journal of neurochemistry.

[16]  William T. Hu,et al.  Plasma epidermal growth factor levels predict cognitive decline in Parkinson disease , 2011, Annals of neurology.

[17]  D. Holtzman,et al.  The Role of Apolipoprotein E in Alzheimer's Disease , 2009, Neuron.

[18]  H. Budka,et al.  Nigral burden of α‐synuclein correlates with striatal dopamine deficit , 2008, Movement disorders : official journal of the Movement Disorder Society.

[19]  T. Dawson.  Faculty Opinions recommendation of A molecular pathway of neurodegeneration linking alpha-synuclein to ApoE and Abeta peptides. , 2008 .

[20]  T. Südhof,et al.  A molecular pathway of neurodegeneration linking α-synuclein to ApoE and Aβ peptides , 2008, Nature Neuroscience.

[21]  Michael Ruse,et al.  Mechanisms and Models , 2007 .

[22]  A. Kakita,et al.  Influences of dopaminergic lesion on epidermal growth factor‐ErbB signals in Parkinson's disease and its model: neurotrophic implication in nigrostriatal neurons , 2005, Journal of neurochemistry.

[23]  Henrik Zetterberg,et al.  APOE ε4 allele is associated with reduced cerebrospinal fluid levels of Aβ42 , 2004, Neurology.

[24]  A. Sidhu,et al.  α‐Synuclein regulation of the dopaminergic transporter: a possible role in the pathogenesis of Parkinson's disease , 2004 .

[25]  A. Sidhu,et al.  Modulation of dopamine transporter function by α‐synuclein is altered by impairment of cell adhesion and by induction of oxidative stress , 2003, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[26]  W. Dauer,et al.  Parkinson's Disease Mechanisms and Models , 2003, Neuron.

[27]  N. Tzourio-Mazoyer,et al.  Automated Anatomical Labeling of Activations in SPM Using a Macroscopic Anatomical Parcellation of the MNI MRI Single-Subject Brain , 2002, NeuroImage.

[28]  Merja Haaparanta,et al.  Decreased striatal dopamine transporter binding in vivo in chronic schizophrenia , 2001, Schizophrenia Research.

[29]  I. Kanazawa,et al.  α‐Synuclein forms a complex with transcription factor Elk‐1 , 2001, Journal of neurochemistry.

[30]  Xin-Fu Zhou,et al.  Roles of transforming growth factor-α and related molecules in the nervous system , 1999, Molecular Neurobiology.

[31]  N. Kubota,et al.  Regulation of dopamine uptake by basic fibroblast growth factor and epidermal growth factor in cultured rat astrocytes , 1999, Neuroscience Research.

[32]  D. Casper,et al.  Epidermal Growth Factor and Basic Fibroblast Growth Factor Protect Dopaminergic Neurons from Glutamate Toxicity in Culture , 1995, Journal of neurochemistry.

[33]  N. Neff,et al.  Epidermal Growth Factor Enhances Striatal Dopaminergic Parameters in the 1‐Methyl‐4‐Phenyl‐l, 2, 3, 6‐Tetrahydropyridine‐Treated Mouse , 1991, Journal of neurochemistry.

[34]  G. Tremblay.  Neuropathology , 1935, Neurology.

[35]  F. Carrillo,et al.  [Elaboration of the SPM template for the standardization of SPECT images with 123I-Ioflupane]. , 2013, Revista espanola de medicina nuclear e imagen molecular.

[36]  Min Shi,et al.  α-Synuclein in cerebrospinal fluid of Alzheimer's disease and mild cognitive impairment. , 2013, Journal of Alzheimer's disease : JAD.

[37]  K. Blennow,et al.  APOE epsilon4 allele is associated with reduced cerebrospinal fluid levels of Abeta42. , 2004, Neurology.

[38]  A. Sidhu,et al.  alpha-Synuclein regulation of the dopaminergic transporter: a possible role in the pathogenesis of Parkinson's disease. , 2004, FEBS letters.

[39]  A. Kakita,et al.  Abnormal expression of epidermal growth factor and its receptor in the forebrain and serum of schizophrenic patients , 2002, Molecular Psychiatry.

[40]  C. Xian,et al.  Roles of transforming growth factor-alpha and related molecules in the nervous system. , 1999, Molecular neurobiology.